| Literature DB >> 35704275 |
Nicholas S Cho1,2,3,4, Akifumi Hagiwara1,2, Jingwen Yao1,2,3, David A Nathanson5, Robert M Prins6, Chencai Wang1,2, Catalina Raymond1,2, Brandon R Desousa5, Ajit Divakaruni5, Danielle H Morrow5, Phioanh L Nghiemphu7,8, Albert Lai7,8, Linda M Liau6, Richard G Everson6, Noriko Salamon2, Whitney B Pope2, Timothy F Cloughesy7,8, Benjamin M Ellingson1,2,3,6,8,9.
Abstract
Amine-weighted chemical exchange saturation transfer (CEST) magnetic resonance imaging (MRI) is particularly valuable as an amine- and pH-sensitive imaging technique in brain tumors, targeting the intrinsically high concentration of amino acids with exchangeable amine protons and reduced extracellular pH in brain tumors. Amine-weighted CEST MRI contrast is dependent on the glioma genotype, likely related to differences in degree of malignancy and metabolic behavior. Amine-weighted CEST MRI may provide complementary value to anatomic imaging in conventional and exploratory therapies in brain tumors, including chemoradiation, antiangiogenic therapies, and immunotherapies. Continual improvement and clinical testing of amine-weighted CEST MRI has the potential to greatly impact patients with brain tumors by understanding vulnerabilities in the tumor microenvironment that may be therapeutically exploited.Entities:
Keywords: Amine CEST; Brain Tumor; CEST EPI; Glioblastoma; Treatment Response; pH Imaging
Year: 2022 PMID: 35704275 DOI: 10.1002/nbm.4785
Source DB: PubMed Journal: NMR Biomed ISSN: 0952-3480 Impact factor: 4.044